# A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

> **NCT00863707** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 511 (actual)

## Conditions studied

- Kidney Diseases
- Coronary Artery Disease

## Interventions

- **DRUG:** Regadenoson
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00863707
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 511 (ACTUAL)
- **Last updated:** 2012-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00863707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00863707, "A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00863707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*